Myeloproliferative neoplasia: a review of clinical criteria and treatment

S. M. Koopmans*, Arienne M. W. van Marion, H. C. Schouten

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review


Essential thrombocythemia (ET), polycythemia vera (PV) and primary myelofibrosis (PMF) belong to the group of Philadelphia chromosome-negative myeloproliferative neoplasia (Ph- MPN). MPNs are clonal bone marrow stem cell disorders characterised by a proliferation of one or more of the myeloid, erythroid or megakaryocytic cell lines. Due to the different affected cell lines, MPNs show typical clinical and histological features. In 2005, a mutation in the JAK2 gene was discovered which generated more insight into the pathogenetic working mechanism of MPNs. However, the treatment of MPN patients is still mainly only palliative, although progress in reducing the symptoms of MPN patients has been made. This review will give a general overview of MPN patients for internal medicine physicians.
Original languageEnglish
Pages (from-to)159-167
JournalNetherlands Journal of Medicine
Issue number4
Publication statusPublished - May 2012


  • MPN
  • myeloproliferative neoplasia
  • essential thrombocythemia
  • polycythemia vera
  • primary myelofibrosis
  • treatment myeloproliferative neoplasia


Dive into the research topics of 'Myeloproliferative neoplasia: a review of clinical criteria and treatment'. Together they form a unique fingerprint.

Cite this